- EUROAPI has been selected by the European Commission to participate in the IPCEI Med4Cure, securing potential funding for pharmaceutical R&D.
- The company aims to enhance the production of macrolide antibiotics, corticosteroids, and nanoparticles through this initiative.
EUROAPI has been chosen by the European Commission as one of the 13 companies eligible to share up to €1 billion in public funding under the Important Project of Common European Interest (IPCEI) Med4Cure. The program, notified by six EU member states, aims to bolster the European pharmaceutical sector by supporting the sustainable and competitive production of essential active pharmaceutical ingredients (APIs).
Announced on 17 June 2024, the IPCEI Med4Cure involves France, Belgium, Hungary, Italy, Slovakia, and Spain. The funding initiative is part of a broader effort to strengthen the European health market, ensuring the availability of critical medicines and fostering new drug delivery solutions. Discussions between the French government and EUROAPI will commence to finalize the contractual agreement for public aid under France 2030.
Through the Med4Cure program, EUROAPI plans to develop three key projects. The company will reshore the production of macrolide antibiotics at its Saint-Aubin-lès-Elbeuf site in France, aiming to expand its market portfolio. At its Vertolaye site, EUROAPI intends to develop advanced processes for corticosteroids, including methylprednisolone, and increase the bioavailability of molecules via nanoparticle technology. These initiatives are expected to address the demand for critical medicines by 2030 and support the development of new drugs.
CEO Ludwig de Mot expressed pride in the selection, stating, “We are proud to have been selected by the European Commission. It is a true recognition of our mission and excellence in R&D. It will help us carry out innovative projects that are key to long-term European sovereignty and which will contribute to the green transition of the pharmaceutical industry.” He emphasized that the projects align with the company’s FOCUS-27 plan, launched in February 2024, aiming for sustainable and profitable growth.
The IPCEI Med4Cure funding will co-fund EUROAPI’s R&D activities up to industrial feasibility studies, enabling the company to develop sustainable production processes within Europe and reinforce its competitive edge in the global pharmaceutical market.
Overview of outsourcing trends 
